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E xtracorporeal membrane oxygenation (ECMO) is a powerful support therapy that has been demon-
strated to increase survival in patients with potentially 
reversible respiratory and circulatory failure [1 , 2].  
Various medications are used to manage the underlying 
illness or complications caused by ECMO therapy [3-5].  
Sedatives are administered to ensure patient safety,  
reduce the metabolic rate and correct the oxygen sup-
ply-demand balance.  Among the available sedatives for 
ECMO treatment,  midazolam (MDZ) is the most com-
monly used [6] because of its low cost and physicians’ 
familiarity with the drug in intensive care.
In ECMO patients,  the distribution volume and 
clearance of administered drugs generally increase as 
the drugs are absorbed by the polyvinyl chloride (PVC) 
tubing and/or membrane oxygenator,  which remark-
ably complicates the pharmacokinetics of the injected 
agents [7-9].  Additionally,  only a few studies have 
reported on preventive measures to reduce the absorp-
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Sedatives are administered during extracorporeal membrane oxygenation (ECMO) therapy to ensure patient 
safety,  reduce the metabolic rate and correct the oxygen supply-demand balance.  However,  the concentrations 
of sedatives can be decreased due to absorption into the circuit.  This study examined factors affecting the 
absorption of a commonly used sedative,  midazolam (MDZ).  Using multiple ex vivo simulation models,  three 
factors that may influence MDZ levels in the ECMO circuit were examined: polyvinyl chloride (PVC) tubing in 
the circuit,  use of a membrane oxygenator in the circuit,  and heparin coating of the circuit.  We also assessed 
changes in drug concentration when MDZ was re-injected in a circuit.  The MDZ level decreased to approxi-
mately 60% of the initial concentration in simulated circuits within the first 30 minutes.  The strongest factor in 
this phenomenon was contact with the PVC tubing.  Membrane oxygenator use tended to increase MDZ loss,  
whereas heparin circuit coating had no influence on MDZ absorption.  Similar results were obtained when a 
second dose of MDZ was injected to the second-use circuits.
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tion caused by heparin coating of the circuit [10 , 11].  
Only a small number of published studies have investi-
gated the pharmacokinetic or pharmacodynamic pro-
files of MDZ in ECMO patients (for review,  see [12]).  
Moreover,  clinical research has been limited by differ-
ences in the conditions and metabolism among studied 
patients,  and differences in the ECMO equipment and 
techniques used.
We hypothesized that three major factors,  PVC tub-
ing in the circuit,  use of a membrane oxygenator in the 
circuit,  and heparin coating of the circuit,  effected the 
loss of MDZ in the circuit.  Using multiple ex vivo sim-
ulation models,  this study aimed to assess the impact of 
each of these three factors on MDZ levels in the ECMO 
circuit.  We also assessed changes in the concentration 
of MDZ upon re-injection into the same circuits.
Materials and Methods
Because this was an experimental simulation study 
and did not include any patients,  the ethical committee 
waived study approval and patient consent.  4 types of 
simulated ECMO circuits were prepared using a reser-
voir,  PVC tubing with or without heparin-coating,  and 
a membrane oxygenator with or without heparin coat-
ing.
Preparation of ECMO circuits. We prepared 4 
types of closed simulated ECMO circuits.  Circuits were 
designed by connecting the arterial and venous cannu-
las to a reservoir bag,  permitting continuous flow of 
priming fluid around the circuit.
Circuits were categorized into 4 groups as follows 
(Table 1).  Group 1: circuits with a heparin-coated 
membrane oxygenator and tubes; Group 2: circuits 
with a non-heparin-coated membrane oxygenator and 
tubes; Group 3: circuits with only heparin-coated 
tubes; and Group 4: circuits with only non-hepa-
rin-coated tubes.  Each group consisted of 4 identically 
prepared circuits.
A PVC tube (Senko Medical Instruments,  Tokyo) of 
120 cm length (3/8 inch diameter; 3/32 inch thickness) 
was used.  Heparin coating was applied to the tubes 
used for Groups 1 and 3.  For the membrane oxygen-
ator,  a silicon-coated external-perfusion hollow-fiber 
polypropylene porous membrane was used; its surface 
area was 2.3 m2.  Heparin coating was applied to the 
membrane oxygenators that were used for Group 1.  In 
each circuit,  a roller pump (HAD-11; Senko Medical 
Instrument) was used to maintain flow.  Each ECMO 
circuit was maintained at 37°C using a temperature 
control unit for artificial heart-lung apparatuses (HHC-
51; Senko Medical Instrument).
Study Phase I: Short-term MDZ absorption.
Short-term MDZ loss was examined in Phase I.  Ten mg 
of MDZ was dissolved in 500-ml normal saline.  The 
concentration of MDZ at this time was defined as P0 
(20 μg/ml).  The total volume of solution was injected 
into the simulated ECMO circuit and priming was con-
ducted.  We maintained flow at 2.0 l/min using a roller 
pump and obtained 1 ml samples from each circuit at 
each of 6 time points: 0.5 h (P1),  1 h (P2),  3 h (P3),  6 h 
(P4),  12 h (P5),  and 24 h (P6) after injection.  Each 
sample was passed through a membrane filter into a 
glass container and cryopreserved at −84°C until analy-
sis.  MDZ absorption and the interactions of MDZ with 
the PVC tubing circuit,  the membrane oxygenator in 
the circuit,  and the heparin circuit coating were 
assessed.
In this paper,  Groups 1 and 2 are collectively 
referred to as the “membrane oxygenator category” and 
Groups 3 and 4 are collectively referred to as the “non- 
membrane oxygenator category.” Similarly,  Groups 1 
and 3 are collectively referred to as the “heparin-coated 
category (in Phase I)” and Groups 2 and 4 are collec-
tively referred to as the “non-heparin-coated category 
(in Phase I).” Each category encompasses eight circuits.
Study Phase II: Long-term MDZ loss and effect of 
MDZ re-injection to the circuit. For the Phase II 
study,  we first quantified the long-term loss of MDZ.  
The circuits from Groups 1 and 2 in Phase I were stored 
at normal temperature for approximately one month;  
these were designated the Group 1’ and Group 2’ cir-
cuits.  Then 1 ml of sample was obtained from each 
circuit and the MDZ concentration was measured (P’ 
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Table 1　 The 4 kinds of simulation circuits studied
Membrane oxygenator Heparin coating
Group 1 Yes Yes
Group 2 Yes No
Group 3 No Yes
Group 4 No No
Simulation circuits were categorized into 4 groups.  Group 1 circuits 
were with heparin-coated membrane oxygenator and tubes,  Group 
2 circuits were with non-heparin-coated membrane oxygenator and 
tubes,  Group 3 circuits were with only heparin-coated tubes,  and 
Group 4 circuits were with only non-heparin-coated tubes.
base line,  P’BL).  Next,  these circuits were used to 
determine whether a circuit which had already 
absorbed MDZ would similarly absorb MDZ a second 
time.  In this experiment,  10 mg of MDZ was dissolved 
in the circuit again,  and P’0 was set as 20 μg/ml above 
the P’BL level.  As in Phase I,  we maintained flow at 
2.0 l/min using the same roller pump and obtained 
1 ml samples from each circuit at six time points: 0.5 h 
(P’1),  1 h (P’2),  3 h (P’3),  6 h (P’4),  12 h (P’5),  and 
24 h (P’6) after MDZ injection.  Each sample was cryo-
preserved using the same method.
Groups 1 and 2 are collectively referred to as the 
“first-use category” and Groups 1’ and 2’ are collectively 
referred to as the “second-use category.” Similarly,  
Groups 1 and 1’ are collectively referred to as the “hep-
arin-coated category (in Phase II)” and Groups 2 and 2’ 
are collectively referred to as the “non-heparin-coated 
category (in Phase II).” Each category encompasses 
eight circuits.
Measurement of MDZ concentration. High per-
formance liquid chromatography was used for quantita-
tive determination of MDZ levels.  A Supersphere 
100RP-18 (e) column was used under the following 
conditions: column temperature of 35°C; mobile 
phase of acetonitrile,  methanol,  phosphate buffer 
(pH 5.0) = 1 : 1 : 1; flow rate of 1.3 ml/min; and sin-
gle-dose injection of 30 μl.  Isopropylantipyrine was 
used as an internal standard substance.
Statistical analysis. Data were expressed as mean 
± standard deviation.  We used a two-way repeated 
measures analysis of variance (ANOVA) to account for 
repetitions within each circuit.  We used the MDZ value 
as a dependent variable and entered the time (i.e.,  time 
comparison),  the conditions (presence or absence of a 
membrane oxygenator; use or non-use of heparin- 
coated tubes; or first or second use of the circuit) (i.e.,  
group comparison),  and an interaction term between 
the time and the conditions (i.e.,  time and group inter-
action) into the model as independent variables.  We 
used the interaction term between dependent variables 
to explore whether changes in the MDZ value between 
time periods differed depending on each condition.  
Statistical analysis was performed using STATA version 
15 (StataCorp LP,  College Station,  TX,  USA).  The 
“anova” command was used for the first run and the 
“regress” command thereafter in order to fit the under-
lying regression model to an ANOVA model using the 
“anova” command.  A p-value below 0.05 was considered 
statistically significant.
Results
A temperature of 37°C was maintained throughout 
the experiments.  ECMO flow was stable and constantly 
maintained at 2.0 l/min.
Study phase I. In Phase I,  the experiment was 
performed using 4 circuits in each of the 4 groups,  and 
6 samples were obtained from each circuit; thus a total 
of 96 samples were analyzed.
In every group,  MDZ levels declined over time 
(Group 1: P1 = 9.9 ± 3.4 μg/ml (50%) to P6 = 5.8 ± 3.1  
μg/ml (29%); Group 2: P1 = 11.0 ± 3.3 μg/ml (55%) to 
P6 = 6.9 ± 3.0 μg/ml (35%); Group 3: P1 = 11.6 ± 2.0 
μg/ml (58%) to P6 = 8.7 ± 4.0 μg/ml (44%); Group 4:  
P1 = 10.7 ± 5.1 μg/ml (54%) to P6 = 10.0 ± 1.9 μg/ml 
(50%).
To observe MDZ absorption into the PVC circuit,  
the reductions in MDZ in Groups 3 and 4 (non-mem-
brane oxygenator category) were examined.  The MDZ 
levels declined by approximately 60% at 0.5 h after initi-
ation of the experiment.  Thereafter the decline was less 
pronounced: at 24 h after initiation of the experiment,  
the MDZ level was 47% lower (P6 = 9.3 μg/ml) com-
pared to that at initiation (P0) of the experiment.
As shown in Fig. 1A,  the presence of a membrane 
oxygenator seemed to have an impact on changes in 
MDZ level,  although the interaction term between time 
and the presence of a membrane oxygenator did not 
reach statistical significance (p = 0.20).  The subsequent 
“regress” command suggested some meaningful inter-
actions (between time and the presence of a membrane 
oxygenator) at P2 (p= 0.017) and P6 (p= 0.06) — i.e.,  the 
declines in MDZ level after one or 24 h tended to be 
larger in the presence of a membrane oxygenator com-
pared to those in the absence of a membrane oxygen-
ator.  Finally,  as shown in Fig. 1B,  heparin coating of 
the circuit had no influence on the changes in MDZ 
level,  and the interaction term was not statistically sig-
nificant (p = 0.79).
Study phase II. After the final MDZ measure-
ment (P6),  all the circuits for Groups 1 and 2 were 
stored at normal temperature for 1 month,  and then the 
drug concentration was measured again.  The mean 
MDZ levels for the 4 circuits after one-month storage 
were 3.0 ± 2.8 μg/ml (15%) and 2.7 ± 3.1 μg/ml (14%) in 
Groups 1 and 2,  respectively,  and both values were 
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approximately 15% lower than the corresponding P6 
levels.  In Phase II,  6 samples were obtained from each 
circuit (2 circuits for each group); a total of 48 samples 
were analyzed.  The MDZ levels declined over time in 
both groups: Group 1’,  P1’ = 12.3 ± 5.1 μg/ml (62%) to 
P6’ = 9.5 ± 6.1 μg/ml (48%); Group 2’,  P1’ = 13.7 ± 5.2  
μg/ml (69%) to P6’ = 9.3 ± 6.1 μg/ml (47%).  The decline 
in MDZ in the groups of the second-use circuit category 
(Groups 1’ and 2’) was similar to that of the first-use 
circuit category.  The final MDZ measurement in the 
Group 1’ and 2’ circuits was slightly (10%) but not 
significantly higher than that of the first-use circuits.
Using the Phase I (Groups 1 and 2) and Phase II 
data,  the factors that may influence MDZ levels within 
a circuit (i.e.,  first- or second-use circuit; presence or 
absence of heparin coating inside a circuit) were exam-
ined.  There was a 10% difference in MDZ absorption 
when comparing the first- or second-use circuit catego-
ries,  but the interaction term did not reach statistical 
significance (p = 0.44) (Fig. 1C).  Circuit heparin coating 
also had no influence on changes in MDZ level,  and 
this interaction term was also not significant (hepa-
rin-coated category vs. non-heparin-coated category) 
(p = 0.64) (Fig. 1D).
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Fig. 1　 A,  Comparison of MDZ levels between groups with or without membrane oxygenators.  Each category contained 8 circuits and 
the interaction terms were statistically signiﬁcant at 1h after administration (P2) (p＝0.017); B,  Comparison of MDZ levels between 
groups with or without heparin coating.  Each category contained 8 circuits and the interaction terms were not signiﬁcant; C,  Comparison 
of MDZ levels between a ﬁrst-use and second-use ECMO circuit.  Each category contained 8 circuits and the interaction terms were not 
signiﬁcant; D,  Comparison of MDZ levels between groups with or without heparin-coating in the second-use circuits.  MDZ: midazolam.  
Each category contained 8 circuits and the interaction terms were not signiﬁcant.
Discussion
Previous pharmacokinetic clinical studies on MDZ 
have been limited by differences among ECMO tech-
niques and devices,  variations in patient clinical back-
grounds,  and small sample sizes.  In addition,  because 
these studies were conducted in an in vivo environment,  
the effects of drug interactions and internal metabolism 
could not be excluded.  In this study,  using a simulated 
ECMO circuit,  we investigated factors that influence 
the absorption of MDZ by the circuit.  The system used 
in this experiment allowed us to examine influences on 
the ECMO circuit alone,  excluding any potential bio-
logical influences.
Our results showed that the use of a membrane oxy-
genator may contribute to a decrease in MDZ concen-
tration,  and second-use circuits appear to make a simi-
lar contribution to the decrease in MDZ.  The membrane 
oxygenator used in our study was made of polypropyl-
ene with a 2.2 m2 surface area.  Polypropylene-based 
membrane oxygenators have been reported to absorb a 
smaller quantity of drugs than silicone-based mem-
brane oxygenators [13].  However,  the surface area of a 
circuit with a membrane oxygenator is 65 times larger 
than that of a circuit without a membrane oxygenator,  
and a larger circuit surface area generally absorbs larger 
amounts of injected agents.  Due to the large surface 
area of the membrane oxygenator,  we expected a more 
dramatic decrease in MDZ level in the circuit with the 
membrane oxygenator.  However,  the difference 
between the membrane oxygenator and non-membrane 
oxygenator groups at 24 h was only 15%.  The polypro-
pylene-based membrane oxygenator in the circuit had 
some impact on the absorption of MDZ,  but its effect 
seemed to be much less than that of the absorption to 
PVC.
PVC is the most commonly used material for con-
duit tubing because of its flexibility,  precise connect-
ability,  and cost-effectiveness.  It has been reported that 
PVC tubing absorbs lipid-soluble agents,  including 
sedatives [14].  In particular,  lipid-soluble drugs with 
high octanol water partition coefficients are very readily 
absorbed into the ECMO circuit [6 , 15 , 16].  MDZ is a 
highly lipid-soluble drug with a protein binding rate of 
97% and a high octanol/water partition coefficient of 
1688.
The mechanism underlying the decrease in lipid sol-
uble drug in the ECMO circuit is absorption (i.e.,  
incorporation of the drug into the material) into the 
plasticizer of the PVC circuit tubing,  not adsorption 
(i.e.,  adherence of the agent to the surface of the mate-
rial).  Generally,  diethylhexyl phthalate (di (2-ethyl-
hexyl) phthalate; DEHP) or trimellitic acid tris (2-eth-
ylhexyl) trimellitate (TOTM) are used as plasticizers for 
PVC.  In the present study,  the tubing plasticizer was 
DEHP.  Previous studies have indicated that MDZ mol-
ecules are absorbed upon exposure to the molecules of 
the DEHP plasticizer [17 , 18].
These chemical properties are considered to contrib-
ute to the decrease in the MDZ concentration due to 
absorption by a PVC tube.  Similar to our experiment,  
MDZ absorption to the entire ECMO circuit,  including 
the membrane oxygenator,  has been reported in other 
research (30 min: 56% absorption; 24 h: 89% absorp-
tion) [19].  Our study showed that even without a mem-
brane oxygenator,  the PVC circuit absorbed approxi-
mately 60% of the MDZ within 30 min.  PVC tubing 
thus seems to be the most determinative factor of MDZ 
absorption in ECMO components.
In general,  coating ECMO circuits with heparin 
decreases neurological or systemic hemorrhagic com-
plications and shortens hospitalization duration [20].  
Such coating can suppress the absorption of certain 
agents,  such as morphine [11],  although the absorption 
rate varies depending on whether heparin or some other 
coating agent is used.  In addition,  other agents such as 
propofol are absorbed to PVC regardless of whether or 
not the circuit is heparin-coated [10].  Indeed,  our 
results indicated that heparin coating did not prevent 
the absorption of MDZ to the ECMO circuit.
We further compared MDZ absorption between a 
first-use and second-use ECMO circuit.  The concentra-
tion of MDZ following a second administration in a 
previously second-use circuit decreased to the same 
extent as the MDZ concentration following the first 
administration.  Mulla et al.  reported that when a dose 
of MDZ to an ECMO circuit exceeded approximately 
30 mg in an in vivo experiment,  the absorption to the 
circuit decreased and the circuit became saturated [21].  
After saturation,  a utilized circuit seems to absorb less 
agent over time [22].  In our present experiments,  the 
full 20 mg dose of MDZ was absorbed without the PVC 
tube becoming saturated.  It is known that MDZ dose 
adjustments and thorough monitoring are required for 
patients with ECMO [23],  especially in the early phase 
of sedation.
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Numerous other factors influence the pharmacoki-
netics in patients treated with ECMO,  and can inhibit 
accurate dosing estimation and injection.  Hemo-
dilution with the priming solution at induction,  
increased distribution of volume-by-volume load to 
maintain intravascular volume after induction [24],  and 
decrease in drug consumption [8] all can influence 
pharmacokinetics during ECMO.  The decrease in drug 
levels in an ECMO circuit is also dependent on the 
individual chemical properties of each drug [7 , 25-27] 
and on drug interactions.  The temperature in the 
ECMO circuit may influence drug absorption [6].  The 
type of driving pump may also be an influencing fac-
tor: lipid-soluble drugs have shown lower absorption in 
centrifugal pumps.  Exposure to oxygen may facilitate 
decreased drug concentration in the circuit [16].  Finally,  
MDZ absorption may become saturated through long-
term continuous infusion to the ECMO circuit [28].
In future studies,  it will be necessary to examine 
other dosing (concentrations) and continuous infusion,  
or a circuit saturated with MDZ.  In addition,  although 
the effects on patients were well-predicted by our ex vivo 
experiments,  it will be necessary to perform an in vivo 
study to definitively demonstrate these effects.  Studies 
on adult patients are required due to the lack of pub-
lished literature describing pharmacokinetic variations 
during ECMO [8] in adult patients; studies on neo-
nates/infants are needed as well.  Finally development 
of alternative flexible circuits formed of materials other 
than PVC and/or development of plasticizers that do not 
absorb MDZ or other agents will be needed.
In conclusion,  the MDZ level rapidly (within 
30 min) decreased from its initial concentration,  
mainly due to absorption into PVC.  The silicone-based 
membrane oxygenator in the circuit also tended to have 
an impact on the absorption of MDZ.  MDZ injected as 
a second dose was absorbed in the circuit in a manner 
similar to the primary injection.  Considering the vari-
ous factors that influence drug absorption,  further in 
vivo research is necessary.
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